RE:FDA Report on MCNA,,,,,,Read last Paragraphi do not recall and i am not going to look back but was the following written after the adcom had met ande said NO.....
FDA is seeking advice from this advisory committee on whether MCNA treatment has a favorable benefit-risk profile in patients with CIS-containing disease refractory to BCG therapy.
Read more at https://www.stockhouse.com/companies/bullboard/bullboard/t.tst/telesta-therapeutics-inc#J6JCsYAAmR4xpuPW.99